ID Corner: What's New in the cUTI World?
by Bessma Dabaan, PharmD, MBA, Stacy Combs, PharmD, BCIDP, Amolee Patel, PharmD, BCPS, BCIDP
The 2025 Infectious Diseases Society of America (IDSA) guideline on complicated urinary tract infections (cUTI) represents a substantial evolution from earlier IDSA guidance, which focused primarily on uncomplicated cystitis and pyelonephritis in women. This new guideline reflects current antimicrobial stewardship principles and prioritizes patient-centered outcomes, including clinical response, recurrence of infection, adverse drug events, and the development and spread of antimicrobial resistance. This update also provides evidence-based support for optimized antimicrobial selection and duration of therapy in cUTI management.
Download PDF
2026 March/April Table of Contents
The 2025 Infectious Diseases Society of America (IDSA) guideline on complicated urinary tract infections (cUTI) represents a substantial evolution from earlier IDSA guidance, which focused primarily on uncomplicated cystitis and pyelonephritis in women. This new guideline reflects current antimicrobial stewardship principles and prioritizes patient-centered outcomes, including clinical response, recurrence of infection, adverse drug events, and the development and spread of antimicrobial resistance. This update also provides evidence-based support for optimized antimicrobial selection and duration of therapy in cUTI management.
Download PDF
2026 March/April Table of Contents